Reducing Excessive Toxicity in Ovarian Cancer Treatment: A Personalized Approach
Authors:
- 15 June 2011
- journal article
- Published by Taylor & Francis in Future Oncology
- Vol. 7 (6) , 789-798
Abstract
The management of ovarian cancer is not only multifactorial, but also patient-specific. Different treatment modalities lead to varying levels of toxicity and individual patient responses, necessitating a personalized approach to each treatment plan. Surgical treatment along with first-line and salvage chemotherapies, are standard modalities but recent innovations in chemotherapy delivery and innovative therapy with mechanism of action are reviewed in this article. Extensive experience with standard chemotherapy has outlined algorithms for managing various toxicities. The focus of treatment may ultimately point towards palliative care and clinicians must be comfortable and well versed in addressing this important option. Overall, management of ovarian cancer requires a multi-faceted approach, keeping the patients' overall health, curative goals and well-being at the forefront. It is nearly impossible to detail exact management plans for every possible toxicity for every patient; formulating personalized treatment plans should be based on evidence and clinician experience, all part of the art of medicine. The objective of this article is to highlight the most frequently encountered and most limiting toxicities of current standard therapies for epithelial ovarian cancer.Keywords
This publication has 62 references indexed in Scilit:
- Place of Death: Correlations With Quality of Life of Patients With Cancer and Predictors of Bereaved Caregivers' Mental HealthJournal of Clinical Oncology, 2010
- Efficacy of Dexmethylphenidate for the Treatment of Fatigue After Cancer Chemotherapy: A Randomized Clinical TrialJournal of Pain and Symptom Management, 2009
- Dose adjustment and supportive care before and during treatmentCancer Treatment Reviews, 2009
- Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative AdministrationClinical Pharmacokinetics, 2009
- Peripheral nerve damage associated with administration of taxanes in patients with cancerCritical Reviews in Oncology/Hematology, 2008
- A multi-institutional evaluation of factors predictive of toxicity and efficacy of bevacizumab for recurrent ovarian cancerInternational Journal of Gynecological Cancer, 2008
- Avoiding bevacizumab related gastrointestinal toxicity for recurrent ovarian cancer by careful patient screeningGynecologic Oncology, 2007
- Experience With Bevacizumab in the Management of Epithelial Ovarian CancerJournal of Clinical Oncology, 2007
- Management and Preparedness for Infusion and Hypersensitivity ReactionsThe Oncologist, 2007
- Treatment goals in ovarian cancerInternational Journal of Gynecological Cancer, 2005